FDA's New Flexible CMC Framework For CGT: What It Means For Cell Therapy Manufacturing

The FDA is signaling a meaningful evolution in how it oversees chemistry, manufacturing, and controls (CMC) for cell and gene therapies. In a January 11 announcement, the agency outlined a more flexible, lifecycle‑based approach that better reflects the realities of CGT development—where small batch sizes, limited patient populations, and rapidly evolving processes are the norm. Rather than relying on traditional validation models that may be impractical for these therapies, the FDA is emphasizing science‑based rationale and risk‑appropriate decision‑making. This shift opens the door for developers to adjust processes as knowledge matures, manage costs more effectively, and keep programs moving without unnecessary regulatory friction.

Explore what these flexible expectations look like in practice, where developers may gain the most leverage, and how to apply this guidance while maintaining safety and quality.